The Associated Press
August 27, 1993, Friday, PM cycle
LOAD-DATE-MDC: August 31, 1993
SECTION: Washington Dateline
LENGTH: 162 words
HEADLINE: Human Trials Should Begin on Antidote to Drug Addiction
BODY: The government should consider allowing human experiments on a case-by-case basis with a controversial anti-addiction drug, an advisory panel concluded.
But the experts advising the Food and Drug Administration did not give a ringing endorsement to ibogaine, a hallucinogen derived from an African plant which sponsors claim holds promise for breaking drug addiction.
At its meeting Thursday the panel was deadlocked over the safety of the drug, which was shown to cause nerve damage in lab rats.
The University of Miami Medical School, the sponsor seeking FDA approval for the human trials, said a one-time use of the ibogaine could cure addiction to heroin, cocaine and other drugs.
The drug abuse advisory committee decided that requests for human trials should be reviewed on a case-by-case basis until more information is available on its link to nerve damage.
The panel’s decision is not binding on the FDA, but the agency usually follows such advice.